Tanai Therapeutics Appoints Pieter Rottiers as CEO
Portfolio - People | Jan 22, 2025 | Qbic Venture Partners
Tanai Therapeutics, a spin-off from VIB focused on novel obesity therapies, has appointed Pieter Rottiers as its new CEO and Director. Rottiers brings a wealth of experience from leading biotech firms such as Precigen ActoBio, Intrexon Actobiotics, and ActoGeniX. His expertise in pioneering early-stage and clinical biotechnology programs positions him to lead Tanai through its next phase of growth. With obesity being a significant global health issue, Tanai’s innovative treatments aim to address this challenge with first-in-class solutions. Supported by a strong investor syndicate led by Qbic Venture Partners and a promising drug target, the company is strategically placed to make a significant impact in tackling obesity and its related health concerns.
Sectors
- Biotechnology
- Pharmaceuticals
Geography
- Belgium – Tanai Therapeutics is based in Ghent, Belgium, and the article emphasizes its activities and new leadership there.
Industry
- Biotechnology – The article focuses on Tanai Therapeutics, a biotech company developing innovative obesity treatments, highlighting advancements and leadership in this industry.
- Pharmaceuticals – Tanai Therapeutics is involved in developing pharmaceutical therapies for obesity, a core aspect of the pharmaceutical sector aiming to tackle significant health challenges.
Financials
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Tanai Therapeutics | Target Company | Company | A VIB spin-off company focusing on pioneering obesity treatments. |
| Pieter Rottiers | Chief Executive Officer & Director | Person | Appointed as CEO to lead Tanai Therapeutics with a strong background in biotech leadership. |
| Qbic Venture Partners | Investor | Company | Private equity firm backing Tanai Therapeutics as part of a strong investor consortium. |